Crinetics Pharmaceuticals, Inc.CRNX

Crinetics Pharmaceuticals, Inc. Segments Disclosure

10-KFiled Feb 26, 20262 min read
Segment Reporting
The Company identifies operating segments based on components of the business for which discrete financial information is available and that are regularly reviewed by the Chief Operating Decision Maker (“CODM”) in allocating resources, assessing performance and monitoring budget versus actuals. The Company’s CODM is its founder and Chief Executive Officer.
The Company operates as a single operating and reportable segment, focused on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine‑related tumors.
The segment derives revenue from product sales and licensing arrangements. The CODM evaluates performance using consolidated net loss, as presented in the consolidated statements of operations and comprehensive loss. Segment assets are represented by total consolidated assets reported in the consolidated balance sheets. Segment depreciation expense and capital expenditures are consistent with the consolidated amounts reported in the consolidated statements of cash flows due to the Company’s single‑segment structure.
Substantially all of the Company’s assets and revenues are generated in the United States. The segment amount of equity method investments is also consistent with the consolidated amount reported in the consolidated balance sheets.
Segment revenue and significant segment expenses which are regularly reported to the CODM are included within the table below and are reconciled to consolidated net loss:
Year ended December 31,
202520242023
Revenue:
Product revenue, net$5,420 $— $— 
Collaboration and license revenue2,276 1,039 4,013 
Total revenue, net7,696 1,039 4,013 
Less:
Cost of product revenue(1,076)— — 
Research and development expenses
Paltusotine(68,337)(51,229)(46,772)
Atumelnant(48,131)(24,524)(13,118)
Other research and development programs(33,322)(26,010)(20,421)
Research and development personnel expenses(102,677)(70,772)(53,446)
Research and development stock-based compensation(50,344)(40,667)(22,633)
Other research and development (1)(29,247)(26,954)(12,137)
Total research and development expenses(332,058)(240,156)(168,527)
Selling, general and administrative
External selling, general and administrative expenses(90,013)(38,733)(20,362)
Selling, general and administrative personnel expenses(60,638)(32,285)(19,428)
Selling, general and administrative stock-based compensation(40,680)(28,719)(18,304)
Total selling, general and administrative expenses(191,331)(99,737)(58,094)
Total other income, net51,632 40,916 13,277 
Income tax expense(180)— — 
Loss on equity method investment— (470)(5,198)
Segment and consolidated net loss$(465,317)$(298,408)$(214,529)
(1)Other research and development is comprised of non-personnel related research and development indirect costs incurred for the benefit of multiple research and development programs, including depreciation, and other facility-based expenses, such as rent expense.

Historical Timeline

Fiscal YearFiled
2025Feb 26, 2026Showing above
2024Feb 27, 2025

About Segments Disclosures

Segment disclosures break a company into its reportable operating units, revealing revenue, profit, and asset allocation that consolidated financial statements obscure. Under ASC 280, segments must match how the chief operating decision maker views the business, providing a window into internal management structure and resource allocation priorities.

Key signals: compare segment margins to identify which units drive profitability and which destroy value. Watch for changes in the number of reportable segments — segment aggregation or disaggregation often coincides with strategic shifts or attempts to obscure declining performance. Intersegment elimination patterns reveal internal pricing practices. The reconciliation between segment totals and consolidated figures exposes corporate overhead allocation and unallocated items. Geographic revenue concentration highlights regulatory and currency exposure. Compare segment-level capital expenditure against segment revenue to assess where management is investing for future growth versus harvesting existing assets.

Other Available Disclosures

Income TaxesRevenueEarnings Per ShareFair ValuePP&ELeasesCommitmentsStock CompensationNew StandardsPay vs Performance